Evaluation of Industry Relationships Among Authors of Clinical Practice Guidelines in Gastroenterology

Evaluation of Financial Conflicts of Interest Among Physician‐Authors of American College of Rheumatology Clinical Practice Guidelines

“…All 3 ACR guidelines adhered to the ACR requirement of having a principal investigator and literature review leader that were conflict‐free, as well as the requirement that the CPG development group be composed of fewer than 51% of authors with conflicts . Our findings—that authors of ACR CPGs have extensive industry financial relationships—parallel the findings of similar, previous investigations in dermatology , orthopedic surgery , urology , otolaryngology , oncology , and gastroenterology .…”

“…US‐based physician‐authors not found in the OPD were assumed to have not received industry payments. We excluded all food and beverage transactions, as this is consistent with the approach taken in previous studies . Payments were extracted in a parallel and blinded manner by 2 investigators (CW and ZZ) using the data download feature on the OPD.…”

Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan

“…Ensuring objectivity and neutrality is important in clinical practice guidelines development, but previous research shows that authors of clinical practice guidelines may become critical marketing promotion targets of pharmaceutical companies [3,9,10]. In reality, they had strong financial conflicts of interest; the authors of national comprehensive cancer centre guidelines received an average of $10 011 in a year [11]; 81.6% of the dermatology [10] and 53% of the gastroenterology clinical practice guideline authors had financial relationships with industrial companies [12]. Similar databases have been developed in Germany and the UK, which also reveal financial ties between the industry and physicians [9,13].…”

Non-Alcoholic Fatty Liver Disease and Disease Mongering

“…7 Sadly, pilling may be the motto: a) there are more than 100 drugs currently going through phase II and III clinical trials for a symptom whose market is estimated to be $1.6bn (£1.2bn; €1.4bn) by 2020; 7 b) the majority of authors of guidelines from the American College of Gastroenterology have financial conflicts of interest with the industry according to Medicaid Services Open Payments database (OPD) but only 34% of financial relationships evidenced by OPD were disclosed. 8…”